Evidence map›Paper›PMID 35013328›Full record

ArticleNature communications2022

Targeted editing and evolution of engineered ribosomes in vivo by filtered editing.

Felix Radford, Shane D Elliott, Alanna Schepartz, Farren J Isaacs

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CRISPR-Cas9-assisted genome editing inbioRxiv : the preprint server for biology · 2024
    Article
  5. Article
  6. Article
  7. Cell-free Biosynthesis of Peptidomimetics.Biotechnology and bioprocess engineering : BBE · 2023
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Felix RadfordDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA.
Shane D ElliottDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA.ORCID http://orcid.org/0000-0003-4182-0753
Alanna SchepartzDepartment of Chemistry, University of California, Berkeley, CA, 94720, USA.
Farren J IsaacsDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, 06520, USA. farren.isaacs@yale.edu.ORCID http://orcid.org/0000-0001-8615-8236
Yale University · USUniversity of California, Berkeley · US

Funding

Predoc Training at the Interface Chemistry and BiologyT32GM067543 · NIGMS · YALE UNIVERSITY · PI CRAWFORD, JASON MICHAEL · 2003 to 2022
$7.4M
Expanding the genetic code with phosphotyrosine and phosphothreonineR01GM125951 · NIGMS · YALE UNIVERSITY · PI ISAACS, FARREN J., RINEHART, JESSE · 2018 to 2021
$1.2M
NIGMS NIH HHS R01 GM125951NIGMS NIH HHS T32 GM067543
6 · The paper itself

Abstract

Genome editing technologies introduce targeted chromosomal modifications in organisms yet are constrained by the inability to selectively modify repetitive genetic elements. Here we describe filtered editing, a genome editing method that embeds group 1 self-splicing introns into repetitive genetic elements to construct unique genetic addresses that can be selectively modified. We introduce intron-containing ribosomes into the E. coli genome and perform targeted modifications of these ribosomes using CRISPR/Cas9 and multiplex automated genome engineering. Self-splicing of introns post-transcription yields scarless RNA molecules, generating a complex library of targeted combinatorial variants. We use filtered editing to co-evolve the 16S rRNA to tune the ribosome's translational efficiency and the 23S rRNA to isolate antibiotic-resistant ribosome variants without interfering with native translation. This work sets the stage to engineer mutant ribosomes that polymerize abiological monomers with diverse chemistries and expands the scope of genome engineering for precise editing and evolution of repetitive DNA sequences.

Indexed as

Genome, BacterialRNA SplicingAnti-Bacterial AgentsCRISPR-Cas SystemsEscherichia coliExonsGene EditingGenetic EngineeringIntronsMutagenesis, Site-DirectedPolymersProtein BiosynthesisRepetitive Sequences, Nucleic AcidRibosomesRNA, Ribosomal, 16SRNA, Ribosomal, 23SAnti-Bacterial AgentsPolymersRNA, Ribosomal, 16SRNA, Ribosomal, 23S

Identifiers

PMID35013328
PMCPMC8748908
OpenAlexW4205336938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.